CALZF (Polynovo) Total Equity: $55.24 Mil (As of Dec. 2025)


CALZF Polynovo Ltd CALZF
74 GF Score
Price $0.62
GF Value $2.21
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Polynovo Total Equity?

Polynovo CALZF 74 Total Equity is $55.24 Mil as of Dec. 2025. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.21 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Polynovo's total equity for the quarter that ended in Dec. 2025 was $55.24 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Polynovo Total Equity Historical Data

* Premium members only.

The historical data trend for Polynovo's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polynovo Total Equity Chart

Polynovo Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.09 12.45 43.88 47.89 54.21

Polynovo Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.22 47.89 47.81 54.21 55.24
CALZF
74GF Score
Polynovo Ltd CALZF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polynovo Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Polynovo's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=82.948-28.741
=54.21

Polynovo's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=81.972-26.729
=55.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $55.24 Mil mean?
Polynovo (CALZF) has a Total Equity of $55.24 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Polynovo and its competitors.
Is Polynovo's Total Equity too high?
Polynovo's current Total Equity is $55.24 Mil. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Total Equity compare to ABT and SYK?
Polynovo's Total Equity of $55.24 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Polynovo and its competitors. Polynovo's current Total Equity is $55.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.21, compared to a current price of $0.62 — trading 71.9% below its estimated fair value. The current Total Equity is $55.24 Mil. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Polynovo (CALZF), the current Total Equity is $55.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polynovo (CALZF) Overvalued in 2026?

Based on GuruFocus' analysis, Polynovo stock appears to be undervalued. The current stock price of $0.62 is trading 71.9% below its estimated GF Value™ of $2.21. GuruFocus considers Polynovo to be Significantly Undervalued.

Key valuation signals for CALZF:

  • Total Equity: $55.24 Mil
  • GF Value™: $2.21 vs. price of $0.62 (71.9% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polynovo Business Description

Other Exchanges MFJ:GermanyPNV:Australia
Address 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score

Get the complete analysis for CALZF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.62
Price
$2.21
GF Value